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Abstract
Multiple organ dysfunction syndrome (MODS) occurs in response
to major insults such as sepsis, severe haemorrhage, trauma, major
surgery and pancreatitis. The mortality rate is high despite intensive
supportive care. The pathophysiological mechanism underlying
MODS are not entirely clear, although several have been pro-
posed. Overwhelming inflammation, immunoparesis, occult oxygen
debt and other mechanisms have been investigated, and - despite
many unanswered questions - therapies targeting these mecha-
nisms have been developed. Unfortunately, only a few inter-
ventions, usually those targeting multiple mechanisms at the same
time, have appeared to be beneficial. We clearly need to under-
stand better the mechanisms that underlie MODS. The endo-
thelium certainly plays an active role in MODS. It functions at the
intersection of several systems, including inflammation, coagula-
tion, haemodynamics, fluid and electrolyte balance, and cell migra-
tion. An important regulator of these systems is the angiopoietin/
Tie2 signalling system. In this review we describe this signalling
system, giving special attention to what is known about it in
critically ill patients and its potential as a target for therapy.
Introduction
Critical illness is a life-threatening disease by definition.
Patients treated for critical illness in the intensive care unit
have underlying causes such as infection, trauma, major
surgery, hemorrhagic shock, pancreatitis and other major
insults. Despite maximal supportive care, severely ill patients
treated in intensive care units are still likely to die, usually after
an episode of increasing failure of multiple organs [1].
The mechanisms that underlie multiple organ dysfunction
syndrome (MODS) are not known [2], although several have
been proposed, including overwhelming infection or immune
response, immune paralysis, occult oxygen debt and mito-
chondrial dysfunction [3-5]. Although these potential mecha-
nisms have features in common, it is not clear whether
MODS is a final common pathway or when it is engaged. The
innate and adaptive immune systems, coagulation, and hor-
monal and neuronal signalling are undoubtedly involved and
are all connected. For example, the hypoxic response is linked
to innate immunity and inflammation by the transcription
factor nuclear factor-κB (NF-κB) [6]. It is no coincidence that
the few interventions that appear to be of benefit, although
this is still under debate, have pleiotropic mechanisms of
action [7-9]. Thus, it seems reasonable to study the inter-
sections between and within cellular and molecular systems to
elucidate the interactions and to develop therapeutic options.
One of the central cellular players in this system is the
endothelial cell (EC). Once thought to serve as an inert
vascular lining, ECs are highly heterogeneous and constitute
an active disseminated organ throughout the circulatory
system. ECs form the border between every organ and the
bloodstream and thus with the rest of the body. The EC
receives and gives signals, stores active substances of
multiple systems, and regulates the passage of fluids, electro-
lytes, proteins and cells. The EC has a time and place
dependent phenotype that is dynamically controlled, and its
reactions to stimuli are specific to organ and vascular bed
[10-13]. The EC merits robust investigation in critical illness,
as in vascular medicine [14].
ECs fulfil three functions. First, they participate in the
formation of new blood vessels. This is important in embryo-
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genesis and organogenesis in normal physiology and in
wound repair, but it is considered pathologic in tumour
growth and diabetes [15]. Second, in the adult organism,
ECs help to maintain homeostasis, including fluid, electrolyte
and protein transport, and cell migration into and out of the
vessel, and to regulate blood flow. Third, ECs react and
respond to disturbances of homeostasis (for example, in
inflammation, coagulation and hypoxia/reperfusion).
All three functions are involved in MODS, in which ECs are
shed, blood flow regulation is hampered, vessels become
leaky, cells migrate out of the vessel and into the surrounding
tissue, and coagulation and inflammation pathways are
activated [16]. The machinery involved - receptors, signalling
pathways and effectors - is largely the same in each function,
but the net effect is determined by the balance between the
parts of the machinery and the context [15].
The angiopoietin/Tie2 signalling system (Ang/Tie system)
appears to be crucial in all three functions [17,18]. The
Ang/Tie system, which was discovered after vascular endo-
thelial growth factor (VEGF) and its receptors, is mainly
restricted to EC regulation and is the focus of this review.
Accumulating evidence suggests that this system is non-
redundant and is involved in multiple MODS-related path-
ways. All components of potential pathophysiological mecha-
nisms in MODS should be viewed within their own context,
because all systems are mutually dependent. Thus, exami-
nation of the Ang/Tie system might offer insight into the
mechanisms underlying MODS and provide opportunities for
therapeutic intervention.
Is the Ang/Tie system involved in critical
illness?
The notion that the Ang/Tie system contributes to disease
pathogenesis is supported by clinical studies and studies in
animal models, and by the relation between symptoms of
critical illness and disturbances in this system. In mice, Ang-2
over-expression in glomeruli causes proteinuria and apoptosis
of glomerular ECs [19]. In a rat model of glomerulonephritis,
Tie2 is over-expressed by ECs, and Ang-1 and Ang-2 are
over-expressed by podocytes in a time-dependent manner
during the repair phase [20]. Therefore, Ang/Tie might be
involved in renal failure and repair.
Lung dysfunction is common in critical illness, and evidence
of Ang/Tie involvement has been found in animal models. In a
rat model of acute respiratory distress syndrome, Ang-1
reduces permeability and inflammation, whereas Tie2
deficiency increases damage [21]. In an experimental model
of asthma, Ang-1 mRNA was decreased, and Ang-1 supple-
mentation decreased alveolar leakage and NF-κB-dependent
inflammation [22]. In hypoxia-induced pulmonary hypertension
in rats, decreased activity of the Tie2 pathway contributed to
right ventricular load, and this effect was antagonized by
Ang-1 [23]. On the other hand, a causative role for Ang-1 in
pulmonary hypertension has also been suggested [24]. In
hyperoxic lung injury, Ang-2 is involved in lung permeability
and inflammation [25].
Ang/Tie also may contribute to critical illness in patients with
pulmonary conditions. Ang-1 and Ang-2 concentrations in
sputum from asthma patients correlated with airway micro-
vascular permeability [26]. In patients with exudative pleural
effusion, the Ang-2 level was increased whereas Ang-1 was
unchanged [27]. Ang-2 levels are associated with pulmonary
vascular leakage and the severity of acute lung injury. Plasma
from patients with acute lung injury and high Ang-2
concentrations disrupts junctional architecture in vitro in
human microvascular ECs [28,29].
Patients with cardiovascular disorders also exhibit changes in
the Ang/Tie system. Circulating Ang-1 concentrations are
stable in patients with atrial fibrillation, but Ang-2 concentra-
tions are increased, along with markers of platelet activation,
angiogenesis and inflammation [30]. Patients with hyper-
tension resulting in end-organ damage have increased levels
of circulating Ang-1, Ang-2, Tie2 and VEGF [31]. Congestive
heart failure is associated with elevated plasma levels of
Ang-2, Tie2 and VEGF, but normal levels of Ang-1 [32]. A
similar pattern is seen in acute coronary syndrome [33].
Circulating levels of components of the Ang/Tie system have
been measured in patients admitted to the critical care unit. In
trauma patients plasma Ang-2, but not plasma Ang-1 or
VEGF, was increased early after trauma, and the level
correlated with disease severity and outcome [34]. In children
with sepsis and septic shock, Ang-2 levels in plasma were
increased and once again correlated with disease severity,
whereas Ang-1 levels were decreased [35]. The same Ang-1/
Ang-2 pattern is seen in adults with sepsis [28,29,36-39].
The results of studies of the Ang/Tie system in humans are
summarized in Table 1. In sepsis, VEGF and its soluble
receptor sFLT-1 (soluble VEGFR-1) are also increased in a
disease severity-dependent manner [40-42].The picture that
emerges from these studies is that the Ang/Tie signalling
system appears to play a crucial role in the symptoms of
MODS. Findings in animal models and in patients suggest
that Ang-1 stabilizes ECs and Ang-2 prepares them for
action. The close relation with VEGF is also apparent.
The angiopoietin signalling system
Ligands and receptors
The angiopoietin signalling system consists of four ligands
and two receptors (Figure 1). The ligands are Ang-1 to
Ang-4, the best studied being Ang-1 and Ang-2 [17,43-45].
The roles of Ang-3 (the murine orthologue of Ang-4) and
Ang-4 are much less clear [18]. Angiopoietins are 70-kDa
glycoproteins that contain an amino-terminal angiopoietin-
specific domain, a coiled-coil domain, a linker peptide and a
carboxyl-terminal fibrinogen homology domain [17,44,46,47].
Ang-1 and Ang-2 bind to Tie2 after polymerization of at leastAvailable online http://ccforum.com/content/13/2/207
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.four (Ang-1) and two (Ang-2) subunits [48,49]. The dis-
similarity between Ang-1 and Ang-2 signalling lies in subtle
differences in the receptor binding domain that lead to
distinct intracellular actions of the receptor; differential
cellular handling of both receptor and ligands after binding
and signalling initiation may also play a role [49,50].
The receptors are Tie1 and Tie2 [51]. Tie2 is a 140-kDa
tyrosine kinase receptor with homology to immunoglobulin
and epidermal growth factor [47,52]. Tie receptors have an
amino-terminal ligand binding domain, a single transmem-
brane domain and an intracellular tyrosine kinase domain [51].
Ligand binding to the extracellular domain of Tie2 results in
receptor dimerization, autophosphorylation and docking of
adaptors, and coupling to intracellular signalling pathways
[47,53-55]. Tie2 is shed from the EC and can be detected in
soluble form in normal human serum and plasma; soluble Tie2
may be involved in ligand scavenging without signalling [56].
Tie2 shedding is both constitutive and induced; the latter can
be controlled by VEGF via a pathway that is dependent on
phosphoinositide-3 kinase (PI3K) and Akt [57]. Shed soluble
Tie2 can scavenge Ang-1 and Ang-2 [56]. Tie1 does not act
as a transmembrane kinase; rather, it regulates the binding of
ligands to Tie2 and modulates its signalling [58-60].
Origin of ligands and distribution of receptors
Ang-1 is produced by pericytes and smooth muscle cells
(Figure 1). In the glomerulus, which lacks pericytes, Ang-1 is
produced by podocytes [61]. Ang-1 has a high affinity for the
extracellular matrix, and so circulating levels do not reflect
tissue levels, which in part is probably responsible for the
constitutive phosphorylation of Tie2 in quiescent endothelium
[62-65]. Ang-2 is produced in ECs and stored in Weibel-
Palade bodies (WPBs) [66,67]. The release of Ang-2 from
WPBs by exocytosis can be regulated independently of the
release of other stored proteins [68]. Tie2 is expressed pre-
dominantly by ECs, although some subsets of macrophages
and multiple other cell types express Tie2 at low levels
[69,70]. In ECs, Tie2 is most abundant in the endothelial
caveolae [71].
Genetics and transcriptional regulation of components
of the Ang/Tie system
The Ang-1 and Ang-2 genes are located on chromosome 8.
Functional polymorphisms have not been identified in the
Ang-1 gene, but three have been identified in the coding
region of Ang-2 [72]. In ECs under stress, Ang-2 mRNA
expression is induced by VEGF, fibroblast growth factor 2
and hypoxia [44,73]. Upregulation of Ang-2 induced by
VEGF and hypoxia can be abolished by inhibiting tyrosine
kinase or mitogen-activated protein kinase [73]. Ang-2 mRNA
expression can be downregulated by Ang-1, Ang-2, or
transforming growth factor [74]. After inhibition of PI3K by
wortmannin, Ang-2 mRNA production is induced by the
transcription factor FOXO1 (forkhead box O1) [75].
EC-specific Ang-2 promoter activity is regulated by Ets-1 and
the Ets family member Elf-1 [76,77]. Because Tie2 signalling
is required under circumstances that usually hamper cell meta-
bolism, its promoter contains repeats that ensure transcription
under difficult circumstances, including hypoxia [78].
The Tie2 downstream signalling pathway
Tie2 is present in phosphorylated form in quiescent and
activated ECs throughout the body [62]. Signalling is initiated
by autophosphorylation of Tie2 after Ang-1 binding and is
conducted by several distinct pathways [54,71,79,80]. Tie2
can also be activated at cell-cell contacts when Ang-1
induces Tie2/Tie2 homotypic intercellular bridges [65]. In
human umbilical vein endothelial cells (HUVECs), Ang/Tie
signalling resulted in 86 upregulated genes and 49 down-
regulated genes [81,82]. Akt phosphorylation by PI3K with
interaction of nitric oxide is the most important intracellular
pathway [51,83-86]; however, ERK1/2, p38MAPK, and
SAPK/JNK can also participate in Ang/Tie downstream
signalling [71,81,84,87-90]. Endothelial barrier control by
Ang-1 requires p190RhoGAP, a GTPase regulator that can
modify the cytoskeleton [80]. The transcription factors
FOXO1, activator protein-1, and NF-κ B are involved in
Ang/Tie-regulated gene transcription [75,91-93]. Ang-1-
induced signalling is has also been implicated in cell
migration induced by reactive oxygen species [94]. ABIN-2
(A20-binding inhibitor of NF-κB 2), an inhibitor of NF-κB, is
involved in Ang-1-regulated inhibition of endothelial apoptosis
and inflammation in HUVECs [93]. However, the downstream
signalling of Tie2 varies depending on cell type and
localization and whether a cell-cell or cell-matrix interaction in
involved, which results in spatiotemporally different patterns
of gene expression. For example, Ang-1/Tie2 signalling leads
to Akt activation within the context of cell-cell interaction, but
it leads to ERK activation in the context of cell-matrix inter-
action. The microenvironment of the receptor in the cell
membrane plays a central role in this signal differentiation.
Adaptor molecules such as DOK and SHP2 and the availa-
bility of substrate determine which protein is phosphorylated
[95].
Signal regulation
After binding of Ang-1, and to a lesser extent Ang-2, Tie2 is
internalized and degraded, and Ang-1 is shed in a reusable form
[50]. VEGF is an important co-factor that can exert different
effects on Ang-1 and Ang-2 signalling [88]. Ang-2 is anti-
apoptotic in the presence of VEGF but induces EC apoptosis in
its absence [96]. Autophosphorylation and subsequent
signalling are inhibited by heteropolymerization of Tie1 and Tie2
[59]. Although the Ang/Tie system appears to play its role
mainly in paracrine and autocrine processes, its circulating
components have been found in plasma. The significance of this
finding in health and disease has yet to be determined.
Summary
The Ang/Tie system is an integrated, highly complex system
of checks and balances (Figure 1) [45,54]. The response of
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and the biological and biomechanical context [97,98]. It is
believed that PI3K/Akt is among the most important down-
stream signalling pathways and that VEGF is one of the most
important modulators of effects. Below we describe in more
detail how this system responds to changes in homeostatic
balances under various conditions of damage and repair.
Ang/Tie signalling system in health and
disease
Angiogenesis, inflammation and homeostasis are highly
related, and the Ang/Tie system lies at the intersection of all
three processes [99,100]. The Ang/Tie system is critically
important for angiogenesis during embryogenesis, but in
healthy adults its function shifts toward maintenance of
homeostasis and reaction to insults. Except for follicle
formation, menstruation and pregnancy, angiogenesis in
adults is disease related. Neoplasia-associated neoangio-
genesis and neovascularization in diabetes and rheumatoid
arthritis are unfavourable events, and improper angiogenesis
is the subject of research in ischaemic disorders and
atherosclerosis. Finally, failure to maintain homeostasis and
an inappropriate reaction to injury are detrimental features in
critical illness.
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Figure 1
A schematic model of the angiopoietin-Tie2 ligand-receptor system. Quiescent endothelial cells are attached to pericytes that constitutively
produce Ang-1. As a vascular maintenance factor, Ang-1 reacts with the endothelial tyrosine kinase receptor Tie2. Ligand binding to the
extracellular domain of Tie2 results in receptor dimerization, autophosphorylation, docking of adaptors and coupling to intracellular signalling
pathways. Signal transduction by Tie2 activates the PI3K/Akt cell survival signalling pathway, thereby leading to vascular stabilization. Tie2
activation also inhibits the NF-κB-dependent expression of inflammatory genes, such as those encoding luminal adhesion molecules (for example,
intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin). Ang-2 is stored and rapidly released from WPBs in an
autocrine and paracrine fashion upon stimulation by various inflammatory agents. Ang-2 acts as an antagonist of Ang-1, stops Tie2 signalling, and
sensitizes endothelium to inflammatory mediators (for example, tumour necrosis factor-α) or facilitates vascular endothelial growth factor-induced
angiogenesis. Ang-2-mediated disruption of protective Ang-1/Tie2 signalling causes disassembly of cell-cell junctions via the Rho kinase pathway.
In inflammation, this process causes capillary leakage and facilitates transmigration of leucocytes. In angiogenesis, loss of cell-cell contacts is a
prerequisite for endothelial cell migration and new vessel formation. Ang, angiopoietin; NF-κB, nuclear factor-κB; PI3K, phosphoinositide-3 kinase;
WPB, Weibel-Palade body.Angiogenesis
Angiogenesis is dependent on multiple growth factors and
receptors and their signalling systems and transcriptional
regulators [101]. The process is complex and encompasses
the recruitment of mobile ECs and endothelial progenitor
cells, the proliferation and apoptosis of these cells, and
reorganization of the surroundings [102]. To form stable new
blood vessels, the response must be coordinated in time and
space, and the Ang/Tie system is involved from beginning to
end. To prepare for angiogenesis, Ang-2 destabilizes quiescent
endothelium through an internal autocrine loop mechanism
[44,103]. Before vascular sprouting starts, focal adhesion
kinase and proteinases such as plasmin and metallo-
proteinases are excreted [85]. Often, this stage is preceded
by activation of innate immunity and inflammation [104].
Apparently, the machinery to clean up after the work has
been finished is installed before the work is commenced,
again illustrating the close relations among the different
processes [104].
Ang-1 maintains and, when required, restores the higher
order architecture of growing blood vessels [43,44,105,106].
This is achieved by inhibiting apoptosis of ECs by Tie2-
mediated activation of PI3K/Akt signalling [107-109]. Ang-1/
Tie2 signalling is involved in angiogenesis induced by cyclic
strain and hypoxia [110,111]. Although its role is less clear,
Tie1 might be involved in EC reactions to shear stress [112].
Ang-1 is a chemoattractant for ECs [83-85], and both Ang-1
and Ang-2 have proliferative effects on those cells [98,113].
At the end of a vascular remodelling phase, Ang-2 induces
apoptosis of ECs for vessel regression in competition with the
survival signal of Ang-1 [106]. This apoptotic process requires
macrophages, which are recruited by Ang-2 [70,114].
ECs require support from surrounding cells such as
pericytes, podocytes, and smooth muscle cells [63]. These
cells actively control vascular behaviour by producing signal-
ling compounds (for instance, Ang-1 and VEGF) that govern
the activity and response of ECs [61]. To attract ECs, Ang-1
secreted by support cells binds to the extracellular matrix. In
quiescent ECs, this binding results in Tie2 movement to the
site of cell-cell interaction. In mobile ECs, Ang-1 polarizes the
cell with Tie2 movement abluminal site [65]. In tumour
angiogenesis and in inflammation, Ang-2 recruits Tie2-
positive monocytes and causes them to release cytokines
and adopt a pro-angiogenic phenotype [111].
Homeostasis
The Ang/Tie system provides vascular wall stability by
inducing EC survival and vascular integrity. However, this
stability can be disrupted by Ang-2 injection, which in healthy
mice causes oedema [28,79,115,116] that can be blocked
by systemic administration of soluble Tie2 [115]. Ang-2 can
impair homeostatic capacity by disrupting cell-cell adhesion
through E-cadherin discharge and EC contraction [28,117].
In contrast, through effects on intracellular signalling, the
cytoskeleton and junction-related molecules, Ang-1 reduces
leakage from inflamed venules by restricting the number and
size of gaps that form at endothelial cell junctions
[80,118,119]. Ang-1 also suppresses expression of tissue
factor induced by VEGF and tumour necrosis factor (TNF)-α,
as well as expression of vascular cell adhesion molecule-1,
intercellular adhesion molecule-1 and E-selectin. As a result,
endothelial inflammation is suppressed [120-123].
In primary human glomerular ECs in vitro, Ang-1 stabilizes the
endothelium by inhibiting angiogenesis, and VEGF increases
water permeability [124]. Similar observations were made in
bovine lung ECs and immortalized HUVECs, in which Ang-1
decreased permeability, adherence of polymorphonuclear
leucocytes and interleukin-8 production [123].
Injury
Reaction to injury can be seen as an attempt to maintain
homeostasis under exceptional conditions. ECs can be
affected by several noxious mechanisms. The Ang/Tie system
is considered crucial in fine-tuning their reaction to injury and
in containing that reaction. Ang-2-deficient mice cannot mount
an inflammatory response to peritonitis induced chemically or
with  Staphylococcus aureus [125], but they can mount a
response to pneumonia, suggesting the existence of inflam-
matory reactions for which Ang-2 is not mandatory. Ang-2
sensitizes ECs to activation by inflammatory cytokines. In
Ang-2-deficient mice, leucocytes do roll on activated endo-
thelium but they are not firmly attached, owing to the lack of
Ang-2-dependent upregulation of adhesion molecules and the
dominance of Ang-1-regulated suppression of adhesion
molecules [120-123,125].
In bovine retinal pericytes, hypoxia and VEGF induce Ang-1
and Tie2 gene expression acutely without altering Ang-2
mRNA levels. The opposite occurs in bovine aortic ECs and
microvascular ECs, underscoring the heterogeneity of ECs
from different microvascular beds [73,126,127].
Lipopolysaccharide (LPS) and pro-inflammatory cytokines
can shift the Ang/Tie balance, rouse ECs from quiescence
and provoke an inflammatory response. In rodents LPS injec-
tion induces expression of Ang-2 mRNA and protein and
reduces the levels of Ang-1, Tie2 and Tie2 phosphorylation in
lung, liver and diaphragm within 24 hours, which may
promote or maintain vascular leakage. The initial increase in
permeability is probably due to release of Ang-2 stored in
WPBs [39,128]. In a mouse model of LPS-induced lung
injury, pulmonary oedema was found to be related to the
balance between VEGF, Ang-1 and Ang-4 [129]. In a com-
parable model, Ang-1-producing transfected cells reduced
alveolar inflammation and leakage [130].
In choroidal ECs, TNF induces Ang-2 mRNA and protein
before affecting Ang-1 and VEGF levels [131]. In HUVECs,
TNF-induced upregulation of Ang-2 is mediated by the NF-κB
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attenuated by both Ang-1 and Ang-2. Without TNF stimu-
lation, only Ang-1 can reduce Tie2 expression [133]. Ang-2
sensitizes ECs to TNF, resulting in enhanced expression of
intercellular adhesion molecule-1, vascular cell adhesion
molecule-1 and E-selectin [74,125,134]. By inhibiting those
endothelial adhesion molecules, Ang-1 decreases leucocyte
adhesion [122].
Angiopoietins can mediate the synthesis of platelet-activating
factor by ECs to stimulate inflammation [90]. Moreover, both
Ang-1 and Ang-2 can translocate P-selectin from WPBs to
the surface of the EC [135], and both can also increase
neutrophil adhesion and chemotaxis and enhance those pro-
cesses when they are induced by interleukin-8 [86,136,137].
In a rat model of haemorrhagic shock, Ang-1 reduced vascular
leakage, and it inhibited microvascular endothelial cell apop-
tosis  in vitro and  in vivo [107,138]. In this model, Ang-1-
promoted cell survival was partly controlled through integrin
adhesion [139]. It has been suggested that EC apoptosis in
haemorrhagic shock contributes to endothelial hyperperme-
ability [140-142]. Apoptosis is one of the reactions to MODS-
related injury as demonstrated in hypoxia/reperfusion [143].
Cell adhesion
Ang-1 and Ang-2 are involved in cell-cell and cell-matrix
binding [139,144-146]. Endothelial permeability is greatly
dependent on cell-cell adhesion. The major adherens junction
is largely composed of vascular-endothelial cadherin. This
complex can be disrupted by VEGF, leading to increased
vascular permeability [147,148], which can be antagonized
by Ang-1 [149,150]. ECs can also bind to the matrix through
the binding of Ang-1 to integrins, which can mediate some of
the effects of Ang-1 without Tie2 phosphorylation [146,151].
At low Ang-1 concentrations, integrin and Tie2 can cooperate
to stabilize ECs [151]. Ang-2 might play a role in inflammatory
diseases such as vasculitis by disrupting the cell-cell junction
and inducing denudation of the basal membrane [152].
Ang-1 can mediate the translocation of Tie2 to endothelial
cell-cell contacts and induce Tie2-Tie2 bridges with signal
pathway activation, leading to diminished paracellular
permeability [65].
Summary
In the mature vessel, Ang-1 acts as a paracrine signal to
maintain a quiescent status quo, whereas Ang-2 induces or
facilitates an autocrine EC response [74,153]. In general,
Ang-1 can be viewed as a stabilizing messenger, causing
continuous Tie2 phosphorylation, and Ang-2 as a de-
stabilizing messenger preparing for action [17]. Attempts to
unravel the exact molecular mechanisms that control the
system are complicated by microenvironment-dependent
endothelial phenotypes and reactivity and by flow type-
dependent reactions to dynamic changes [13,154,155].
Hence, the EC must be viewed in the context of its
surroundings - the pericyte at the abluminal site, and the
blood and its constituents on the luminal site [64]. The
Ang/Tie system certainly functions as one of the junctions in
signal transduction and plays a key role in multiple cellular
processes, many of which have been linked to MODS.
Targeting the Ang/Tie system in critical
illness
A therapy should intervene in the right place and at the right
time, with the proper duration of action and without collateral
damage [156,157]. The Ang/Tie system is involved in many
processes and lies at the intersection of molecular mecha-
nisms of disease. Thus, interventions targeting this system
might have benefits. As in other pleiotropic systems, however,
unexpected and unwanted side effects are a serious risk. The
absence of redundant systems to take over the function of
Ang/Tie2 has the advantage that the effect of therapeutic
intervention cannot easily be bypassed by the cell. On the
other hand, because the cell has no escape, the effect may
become uncontrolled and irreversible. Moreover, the exact
function of the Ang/Tie system in the pathological cascade is
not fully established. What we see in animal models and in
patients is most probably the systemic reflection of a local
process. We do not know whether this systemic reflection is
just a marker of organ injury or even a mediator of distant
organ involvement.
Of the three main functions of the Ang/Tie system, it is mainly
angiogenesis that has been evaluated as a therapeutic target.
So far, the focus of Ang/Tie modulation has been on inhibit-
ing angiogenesis related to malignant and ophthalmological
diseases and to complications of diabetes [158,159]. In
peripheral arterial occlusive disease, stimulation of angio-
genesis seems a logical strategy to attenuate the conse-
quences of ongoing tissue ischaemia. In a rat model of hind
limb ischaemia, combined delivery of Ang-1 and VEGF genes
stimulated collateral vessel development to the greatest
extent [160,161]. Thus far, therapy directed at VEGF has
reached the clinic, but not therapy directed at Ang/Tie [162].
Targeting homeostasis and repair/inflammation in critically ill
patients is an attractive option and has already led to the
development of new drugs [45,158,163]. From current know-
ledge, one can speculate about the best options for therapy
aimed at the Ang/Tie system. In critical illness, Ang-1 is
considered to be the ‘good guy’ because it can create
vascular stability and thus its activity should be supported. In
contrast, Ang-2 appears to be a ‘bad guy’ that induces
vascular leakage, so its activity should be inhibited [164].
Production of recombinant Ang-1 is technically challenging
as Ang-1 is ‘sticky’ because of its high affinity for the
extracellular matrix [165]. However, stable Ang-1 variants
with improved receptor affinity have been engineered. A
stable soluble Ang-1 variant has anti-permeability activity
[165]. When injected intraperitoneally in mice, human
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permeability [80]. In diabetic mice, a stable Ang-1 derivative
attenuated proteinuria and delayed renal failure [166], and
manipulating the Ang-1/Ang-2 ratio changed infarct size
[167]. A more profound Ang-1 effect can be achieved by
locally stimulating Ang-1 production. In experimental acute
respiratory distress syndrome, transfected cells expressing
Ang-1 reduced alveolar inflammation and leakage [130]. An
adenovirus construct encoding Ang-1 protected mice from
death in an LPS model, and Ang-1 gene therapy reduced
acute lung injury in a rat model [21,168,169]. In hypertensive
rats, a plasmid expressing a stable Ang-1 protein reduced
blood pressure and end-organ damage [170]. If used in a
disease with a limited duration, as critical illness should be,
virus/plasmid-driven production of Ang-1 could easily be shut
down when it is no longer needed.
Manipulating Ang-2 activity is also difficult. Ang-2 stored in
WPBs is rapidly released and must be captured immediately
to prevent autocrine/paracrine disruption of protective Ang-1/
Tie signalling. Soluble Tie2 or Ang-2 inhibitors should be
effective [26,171]. Neutralizing antibodies against Ang-2
might also be an option. Replenishment of Ang-2 stores
could be abolished by small interfering RNA techniques or
spiegelmer/aptamer approaches [25,172,173].
However, no bad guy is all bad, and no good guy is all good.
For example, Ang-1 has been linked to the development of
pulmonary hypertension [174]. Also, under certain circum-
stances Ang-2 can act as a Tie2 agonist and exert effects
similar to those of Ang-1 - an unexplained finding that illus-
trates our limited understanding of the Ang/Tie system [75].
Complete blockade of Ang-2 might also hamper innate
immunity and revascularization.
Finding the right balance and timing will be the major challenge
when developing therapies to target the Ang/Tie system. In the
meantime, we might have already used Ang/Tie-directed
therapy with the most pleiotropic of all drugs - corticosteroids.
In the airways, steroids suppressed Ang-2 and increased
Ang-1 expression [26,171,175]. Interventions further down-
stream targeting specific adaptor molecules, signalling path-
ways, or transcription factors have yet to be explored.
Diagnostic and prognostic opportunities
In patients with malignant disease, the Ang/Tie system might
serve as a tumour or response marker. In patients with
multiple myeloma, normalization of the Ang-1/Ang-2 ratio
reflects a response to treatment with anti-angiogenesis
medication [176]. In patients with non-small-cell lung cancer,
Ang-2 is increased in serum and indicates tumour
progression [177]. After allogeneic stem cell transplantation
in patients with high-risk myeloid malignancies, the serum
Ang-2 concentration predicts disease-free survival [178],
possibly reflecting a relation between cancer-driven angio-
genesis and Ang-2 serum level.
In nonmalignant disease, the levels of Ang/Tie system com-
ponents correlate with disease severity [28,29,34-37,39].
However, current data are insufficient to justify the use of
serum soluble Tie2/Ang levels for diagnostic and prognostic
purposes. In critical illness, assessment of the Ang/Tie
system in patients with different severities of disease and with
involvement of different organ systems might help to define
our patient population and allow us to rethink our concepts of
MODS. In this way, such work may lead to enhanced
diagnosis and prognostication in the future [2].
Conclusions
Accumulating evidence from animal and human studies
points to the involvement of the Ang/Tie system in vascular
barrier dysfunction during critical illness. Many processes in
injury and in repair act through this nonredundant system.
Thus far, only preliminary studies in critically ill patients have
been reported. Methods to manipulate this system are
available but have not been tested in such patients. The
response to treatment is difficult to predict because of the
pleiotropic functions of the Ang/Tie system, because the
balance among its components appears to be more important
than the absolute levels, and because the sensitivity of the
endothelium to disease-related stimuli varies, depending on
the environment and the organ involved. To avoid disappoint-
ment, further experimental and translational research must be
carried out, and Ang/Tie modulation must not be introduced
into the clinic prematurely. Implementing the results of this
research in critical care represents an opportunity to show
what we have learned [2]. Ang/Tie signalling is a very
promising target and must not be allowed to become lost in
translation [179].
Competing interests
The author(s) declare that they have no competing interests.
References
1. Wenzel RP: Treating sepsis. N Engl J Med 2002, 347:966-967.
2. Marshall JC: Sepsis: rethinking the approach to clinical
research. J Leukoc Biol 2008, 83:471-482.
3. Singer M, De Santis V, Vitale D, Jeffcoate W: Multiorgan failure
is an adaptive, endocrine-mediated, metabolic response to
overwhelming systemic inflammation. Lancet 2004, 364:545-
548.
4. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care
Med 1996, 24:1125-1128.
5. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP,
Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in
patients with sepsis, shock, and multiple organ dysfunction.
Crit Care Med 1999, 27:1230-1251.
6. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS,
Nizet V, Johnson RS, Haddad GG, Karin M: NF-kappaB links
innate immunity to the hypoxic response through transcrip-
tional regulation of HIF-1alpha. Nature 2008, 453:807-811.
7. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF,
Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely
EW, Fisher CJ Jr: Efficacy and safety of recombinant human
activated protein C for severe sepsis. N Engl J Med 2001, 344:
699-709.
8. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B,
Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-
Riffaut P, Bellissant E: Effect of treatment with low doses of
hydrocortisone and fludrocortisone on mortality in patients
Critical Care    Vol 13 No 2 van Meurs et al.
Page 8 of 13
(page number not for citation purposes)with septic shock. JAMA 2002, 288:862-871.
9. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyn-
inckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouil-
lon R: Intensive insulin therapy in the critically ill patients. N
Engl J Med 2001, 345:1359-1367.
10. Aird WC: Phenotypic heterogeneity of the endothelium: I.
Structure, function, and mechanisms. Circ Res 2007, 100:158-
173.
11. Aird WC: Phenotypic heterogeneity of the endothelium: II.
Representative vascular beds. Circ Res 2007, 100:174-190.
12. van Meurs M, Wulfert FM, Knol AJ, de Haes A, Houwertjes M,
Aarts LP, Molema G: Early organ-specific endothelial activation
during hemorrhagic shock and resuscitation. Shock 2008, 29:
291-299.
13. Langenkamp E, Molema G: Microvascular endothelial cell het-
erogeneity: general concepts and pharmacological conse-
quences for anti-angiogenic therapy of cancer. Cell Tissue Res
2009, 335:205-222.
14. Aird WC: The role of the endothelium in severe sepsis and
multiple organ dysfunction syndrome. Blood 2003, 101:3765-
3777.
15. Bouis D, Kusumanto Y, Meijer C, Mulder NH, Hospers GA: A
review on pro- and anti-angiogenic factors as targets of clini-
cal intervention. Pharmacol Res 2006, 53:89-103.
16. Rafat N, Hanusch C, Brinkkoetter PT, Schulte J, Brade J, Zijlstra
JG, van der Woude FJ, van AK, Yard BA, Beck GC: Increased
circulating endothelial progenitor cells in septic patients: cor-
relation with survival. Crit Care Med 2007, 35:1677-1684.
17. Brindle NP, Saharinen P, Alitalo K: Signaling and functions of
angiopoietin-1 in vascular protection. Circ Res 2006, 98:1014-
1023.
18. Jones PF: Not just angiogenesis: wider roles for the angiopoi-
etins. J Pathol 2003, 201:515-527.
19. Davis B, Dei CA, Long DA, White KE, Hayward A, Ku CH, Woolf
AS, Bilous R, Viberti G, Gnudi L: Podocyte-specific expression
of angiopoietin-2 causes proteinuria and apoptosis of
glomerular endothelia. J Am Soc Nephrol 2007, 18:2320-2329.
20. Campean V, Karpe B, Haas C, Atalla A, Peters H, Rupprecht H,
Liebner S, Acker T, Plate K, Amann K: Angiopoietin 1 and 2
gene and protein expression is differentially regulated in
acute anti-Thy1.1 glomerulonephritis. Am J Physiol Renal
Physiol 2008, 294:F1174-F1184.
21. McCarter SD, Mei SH, Lai PF, Zhang QW, Parker CH, Suen RS,
Hood RD, Zhao YD, Deng Y, Han RN, Dumont DJ, Stewart DJ:
Cell-based angiopoietin-1 gene therapy for acute lung injury.
Am J Respir Crit Care Med 2007, 175:1014-1026.
22. Simoes DC, Vassilakopoulos T, Toumpanakis D, Petrochilou K,
Roussos C, Papapetropoulos A: Angiopoietin-1 protects
against airway inflammation and hyperreactivity in asthma.
Am J Respir Crit Care Med 2008, 177:1314-1321.
23. Kugathasan L, Dutly AE, Zhao YD, Deng Y, Robb MJ, Keshavjee
S, Stewart DJ: Role of angiopoietin-1 in experimental and
human pulmonary arterial hypertension. Chest 2005,  128
(suppl):633S-642S.
24. Rudge JS, Thurston G, Yancopoulos GD: Angiopoietin-1 and
pulmonary hypertension: cause or cure? Circ Res 2003, 92:
947-949.
25. Bhandari V, Choo-Wing R, Lee CG, Zhu Z, Nedrelow JH, Chupp
GL, Zhang X, Matthay MA, Ware LB, Homer RJ, Lee PJ, Geick A,
de Fougerolles AR, Elias JA: Hyperoxia causes angiopoietin 2-
mediated acute lung injury and necrotic cell death. Nat Med
2006, 12:1286-1293.
26. Kanazawa H, Nomura S, Asai K: Roles of angiopoietin-1 and
angiopoietin-2 on airway microvascular permeability in asth-
matic patients. Chest 2007, 131:1035-1041.
27. Kalomenidis I, Kollintza A, Sigala I, Papapetropoulos A, Papiris S,
Light RW, Roussos C: Angiopoietin-2 levels are elevated in
exudative pleural effusions. Chest 2006, 129:1259-1266.
28. Parikh SM, Mammoto T, Schultz A, Yuan HT, Christiani D, Karu-
manchi SA, Sukhatme VP: Excess circulating angiopoietin-2
may contribute to pulmonary vascular leak in sepsis in
humans. PLoS Med 2006, 3:e46.
29. Gallagher DC, Parikh SM, Balonov K, Miller A, Gautam S, Talmor
D, Sukhatme VP: Circulating angiopoietin 2 correlates with
mortality in a surgical population with acute lung injury/adult
respiratory distress syndrome. Shock 2008, 29:656-661.
30. Choudhury A, Freestone B, Patel J, Lip GY: Relationship of
soluble CD40 ligand to vascular endothelial growth factor,
angiopoietins, and tissue factor in atrial fibrillation: a link
among platelet activation, angiogenesis, and thrombosis?
Chest 2007, 132:1913-1919.
31. Nadar SK, Blann A, Beevers DG, Lip GY: Abnormal angiopoi-
etins 1&2, angiopoietin receptor Tie-2 and vascular endothe-
lial growth factor levels in hypertension: relationship to target
organ damage [a sub-study of the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT)]. J Intern Med 2005,  258:
336-343.
32. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY: Plasma
angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2
levels in congestive heart failure. J Am Coll Cardiol 2004, 43:
423-428.
33. Lee KW, Lip GY, Blann AD: Plasma angiopoietin-1, angiopoi-
etin-2, angiopoietin receptor tie-2, and vascular endothelial
growth factor levels in acute coronary syndromes. Circulation
2004, 110:2355-2360.
34. Ganter MT, Cohen MJ, Brohi K, Chesebro BB, Staudenmayer KL,
Rahn P, Christiaans SC, Bir ND, Pittet JF: Angiopoietin-2,
marker and mediator of endothelial activation with prognostic
significance early after trauma? Ann Surg 2008, 247:320-326.
35. Giuliano JS Jr, Lahni PM, Harmon K, Wong HR, Doughty LA, Car-
cillo JA, Zingarelli B, Sukhatme VP, Parikh SM, Wheeler DS:
Admission angiopoietin levels in children with septic shock.
Shock 2007, 28:650-654.
36. Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, Haller H,
Kumpers P: Circulating angiopoietin-1 and -2 in critically ill
patients - development and clinical application of two new
immunoassays. Crit Care 2008, 12:R94.
37. Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S,
Dimopoulou I, Sotiropoulou C, Zakynthinos S, Armaganidis A,
Papapetropoulos A, Roussos C: Angiopoietin-2 is increased in
severe sepsis: correlation with inflammatory mediators. Crit
Care Med 2007, 35:199-206.
38. Siner JM, Bhandari V, Engle KM, Elias JA, Siegel MD: Elevated
serum angiopoietin 2 levels are associated with increased
mortality in sepsis. Shock 2008 [Epub ahead of print].
39. van der Heijden M, Nieuw Amerongen GP, Koolwijk P, van Hins-
bergh VW, Groeneveld AB: Angiopoietin-2, permeability
oedema, occurrence and severity of ALI/ARDS in septic and
non-septic critically ill patients. Thorax 2008, 63:903-909.
40. Shapiro NI, Yano K, Okada H, Fischer C, Howell M, Spokes KC,
Ngo L, Angus DC, Aird WC: A prospective, observational study
of soluble FLT-1 and vascular endothelial growth factor in
sepsis. Shock 2008, 29:452-457.
41. van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoe-
pelman AI, Geelen SP: Plasma vascular endothelial growth
factor in severe sepsis. Shock 2005, 23:35-38.
42. Pickkers P, Sprong T, Eijk L, van der Hoeven H, Smits P, Deuren
M: Vascular endothelial growth factor is increased during the
first 48 hours of human septic shock and correlates with vas-
cular permeability. Shock 2005, 24:508-512.
43. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis
S, Sato TN, Yancopoulos GD: Requisite role of angiopoietin-1,
a ligand for the TIE2 receptor, during embryonic angiogene-
sis. Cell 1996, 87:1171-1180.
44. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ,
Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopou-
los N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-
2, a natural antagonist for Tie2 that disrupts in vivo
angiogenesis. Science 1997, 277:55-60.
45. Makinde T, Agrawal DK: Intra and extravascular transmem-
brane signalling of angiopoietin-1-Tie2 receptor in health and
disease. J Cell Mol Med 2008, 12:810-828.
46. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V,
Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos
GD: Isolation of angiopoietin-1, a ligand for the TIE2 receptor,
by secretion-trap expression cloning. Cell 1996,  87:1161-
1169.
47. Jones N, Iljin K, Dumont DJ, Alitalo K: Tie receptors: new modu-
lators of angiogenic and lymphangiogenic responses. Nat Rev
Mol Cell Biol 2001, 2:257-267.
48. Kim KT, Choi HH, Steinmetz MO, Maco B, Kammerer RA, Ahn SY,
Kim HZ, Lee GM, Koh GY: Oligomerization and multimeriza-
tion are critical for angiopoietin-1 to bind and phosphorylate
Tie2. J Biol Chem 2005, 280:20126-20131.
Available online http://ccforum.com/content/13/2/207
Page 9 of 13
(page number not for citation purposes)49. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T,
Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A, Goldberg J,
Jain V, Bailey K, Karow M, Fandl J, Samuelsson SJ, Ioffe E, Rudge
JS, Daly TJ, Radziejewski C, Yancopoulos GD: Angiopoietins
have distinct modular domains essential for receptor binding,
dimerization and superclustering. Nat Struct Biol 2003, 10:38-
44.
50. Bogdanovic E, Nguyen VP, Dumont DJ: Activation of Tie2 by
angiopoietin-1 and angiopoietin-2 results in their release and
receptor internalization. J Cell Sci 2006, 119:3551-3560.
51. Peters KG, Kontos CD, Lin PC, Wong AL, Rao P, Huang L,
Dewhirst MW, Sankar S: Functional significance of Tie2 signal-
ing in the adult vasculature. Recent Prog Horm Res 2004, 59:
51-71.
52. Macdonald PR, Progias P, Ciani B, Patel S, Mayer U, Steinmetz
MO, Kammerer RA: Structure of the extracellular domain of Tie
receptor tyrosine kinases and localization of the angiopoietin-
binding epitope. J Biol Chem 2006, 281:28408-28414.
53. Hubbard SR, Till JH: Protein tyrosine kinase structure and
function. Annu Rev Biochem 2000, 69:373-398.
54. Eklund L, Olsen BR: Tie receptors and their angiopoietin
ligands are context-dependent regulators of vascular remod-
eling. Exp Cell Res 2006, 312:630-641.
55. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly
R, Alitalo K, Dumont DJ: Identification of Tek/Tie2 binding part-
ners. Binding to a multifunctional docking site mediates cell
survival and migration. J Biol Chem 1999, 274:30896-30905.
56. Reusch P, Barleon B, Weindel K, Martiny-Baron G, Godde A,
Siemeister G, Marme D: Identification of a soluble form of the
angiopoietin receptor TIE-2 released from endothelial cells
and present in human blood. Angiogenesis 2001, 4:123-131.
57. Findley CM, Cudmore MJ, Ahmed A, Kontos CD: VEGF induces
Tie2 shedding via a phosphoinositide 3-kinase/Akt depen-
dent pathway to modulate Tie2 signaling. Arterioscler Thromb
Vasc Biol 2007, 27:2619-2626.
58. Marron MB, Singh H, Tahir TA, Kavumkal J, Kim HZ, Koh GY,
Brindle NP: Regulated proteolytic processing of Tie1 modu-
lates ligand responsiveness of the receptor-tyrosine kinase
Tie2. J Biol Chem 2007, 282:30509-30517.
59. Yuan HT, Venkatesha S, Chan B, Deutsch U, Mammoto T,
Sukhatme VP, Woolf AS, Karumanchi SA: Activation of the
orphan endothelial receptor Tie1 modifies Tie2-mediated
intracellular signaling and cell survival. FASEB J 2007,  21:
3171-3183.
60. Kim KL, Shin IS, Kim JM, Choi JH, Byun J, Jeon ES, Suh W, Kim
DK: Interaction between Tie receptors modulates angiogenic
activity of angiopoietin2 in endothelial progenitor cells. Car-
diovasc Res 2006, 72:394-402.
61. Hirschberg R, Wang S, Mitu GM: Functional symbiosis
between endothelium and epithelial cells in glomeruli. Cell
Tissue Res 2008, 331:485-493.
62. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS,
Peters KG: Tie2 expression and phosphorylation in angio-
genic and quiescent adult tissues. Circ Res 1997, 81:567-574.
63. Armulik A, Abramsson A, Betsholtz C: Endothelial/pericyte
interactions. Circ Res 2005, 97:512-523.
64. Bergers G, Song S: The role of pericytes in blood-vessel for-
mation and maintenance. Neuro Oncol 2005, 7:452-464.
65. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A,
Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY,
Olsen BR, Alitalo K: Angiopoietins assemble distinct Tie2 sig-
nalling complexes in endothelial cell-cell and cell-matrix con-
tacts. Nat Cell Biol 2008, 10:527-537.
66. Metcalf DJ, Nightingale TD, Zenner HL, Lui-Roberts WW, Cutler
DF: Formation and function of Weibel-Palade bodies. J Cell
Sci 2008, 121:19-27.
67. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V,
Schmidt JM, Kriz W, Thurston G, Augustin HG: The Tie-2 ligand
angiopoietin-2 is stored in and rapidly released upon stimula-
tion from endothelial cell Weibel-Palade bodies. Blood 2004,
103:4150-4156.
68. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J:
Dynamics and plasticity of Weibel-Palade bodies in endothe-
lial cells. Arterioscler Thromb Vasc Biol 2006, 26:1002-1007.
69. Lewis CE, De PM, Naldini L: Tie2-expressing monocytes and
tumor angiogenesis: regulation by hypoxia and angiopoietin-
2. Cancer Res 2007, 67:8429-8432.
70. De Palma M., Murdoch C, Venneri MA, Naldini L, Lewis CE: Tie2-
expressing monocytes: regulation of tumor angiogenesis and
therapeutic implications. Trends Immunol 2007, 28:519-524.
71. Yoon MJ, Cho CH, Lee CS, Jang IH, Ryu SH, Koh GY: Localiza-
tion of Tie2 and phospholipase D in endothelial caveolae is
involved in angiopoietin-1-induced MEK/ERK phosphorylation
and migration in endothelial cells. Biochem Biophys Res
Commun 2003, 308:101-105.
72. Ward EG, Grosios K, Markham AF, Jones PF: Genomic struc-
tures of the human angiopoietins show polymorphism in
angiopoietin-2. Cytogenet Cell Genet 2001, 94:147-154.
73. Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y:
Hypoxia and vascular endothelial growth factor selectively up-
regulate angiopoietin-2 in bovine microvascular endothelial
cells. J Biol Chem 1999, 274:15732-15739.
74. Mandriota SJ, Pepper MS: Regulation of angiopoietin-2 mRNA
levels in bovine microvascular endothelial cells by cytokines
and hypoxia. Circ Res 1998, 83:852-859.
75. Daly C, Pasnikowski E, Burova E, Wong V, Aldrich TH, Griffiths J,
Ioffe E, Daly TJ, Fandl JP, Papadopoulos N, McDonald DM,
Thurston G, Yancopoulos GD, Rudge JS: Angiopoietin-2 func-
tions as an autocrine protective factor in stressed endothelial
cells. Proc Natl Acad Sci USA 2006, 103:15491-15496.
76. Hegen A, Koidl S, Weindel K, Marme D, Augustin HG, Fiedler U:
Expression of angiopoietin-2 in endothelial cells is controlled
by positive and negative regulatory promoter elements. Arte-
rioscler Thromb Vasc Biol 2004, 24:1803-1809.
77. Hasegawa Y, Abe M, Yamazaki T, Niizeki O, Shiiba K, Sasaki I,
Sato Y: Transcriptional regulation of human angiopoietin-2 by
transcription factor Ets-1. Biochem Biophys Res Commun
2004, 316:52-58.
78. Park EH, Lee JM, Blais JD, Bell JC, Pelletier J: Internal translation
initiation mediated by the angiogenic factor Tie2. J Biol Chem
2005, 280:20945-20953.
79. Mehta D, Malik AB: Signaling mechanisms regulating endothe-
lial permeability. Physiol Rev 2006, 86:279-367.
80. Mammoto T, Parikh SM, Mammoto A, Gallagher D, Chan B,
Mostoslavsky G, Ingber DE, Sukhatme VP: Angiopoietin-1
requires p190 RhoGAP to protect against vascular leakage in
vivo. J Biol Chem 2007, 282:23910-23918.
81. Abdel-Malak NA, Harfouche R, Hussain SN: Transcriptome of
angiopoietin 1-activated human umbilical vein endothelial
cells. Endothelium 2007, 14:285-302.
82. Chen SH, Babichev Y, Rodrigues N, Voskas D, Ling L, Nguyen
VP, Dumont DJ: Gene expression analysis of Tek/Tie2 signal-
ing. Physiol Genomics 2005, 22:257-267.
83. Babaei S, Teichert-Kuliszewska K, Zhang Q, Jones N, Dumont DJ,
Stewart DJ: Angiogenic actions of angiopoietin-1 require
endothelium-derived nitric oxide. Am J Pathol 2003, 162:1927-
1936.
84. Harfouche R, Hassessian HM, Guo Y, Faivre V, Srikant CB, Yan-
copoulos GD, Hussain SN: Mechanisms which mediate the
antiapoptotic effects of angiopoietin-1 on endothelial cells.
Microvasc Res 2002, 64:135-147.
85. Kim I, Kim HG, Moon SO, Chae SW, So JN, Koh KN, Ahn BC,
Koh GY: Angiopoietin-1 induces endothelial cell sprouting
through the activation of focal adhesion kinase and plasmin
secretion. Circ Res 2000, 86:952-959.
86. Brkovic A, Pelletier M, Girard D, Sirois MG: Angiopoietin chemo-
tactic activities on neutrophils are regulated by PI-3K activa-
tion. J Leukoc Biol 2007, 81:1093-1101.
87. Harfouche R, Gratton JP, Yancopoulos GD, Noseda M, Karsan A,
Hussain SN: Angiopoietin-1 activates both anti- and proapop-
totic mitogen-activated protein kinases. FASEB J 2003,  17:
1523-1525.
88. Harfouche R, Hussain SN: Signaling and regulation of endothe-
lial cell survival by angiopoietin-2. Am J Physiol Heart Circ
Physiol 2006, 291:H1635-H1645.
89. Kim I, Kim JH, Moon SO, Kwak HJ, Kim NG, Koh GY: Angiopoi-
etin-2 at high concentration can enhance endothelial cell sur-
vival through the phosphatidylinositol 3’-kinase/Akt signal
transduction pathway. Oncogene 2000, 19:4549-4552.
90. Maliba R, Lapointe S, Neagoe PE, Brkovic A, Sirois MG:
Angiopoietins-1 and -2 are both capable of mediating
endothelial PAF synthesis: intracellular signalling pathways.
Cell Signal 2006, 18:1947-1957.
91. Abdel-Malak NA, Srikant CB, Kristof AS, Magder SA, Di Battista
Critical Care    Vol 13 No 2 van Meurs et al.
Page 10 of 13
(page number not for citation purposes)JA, Hussain SN: Angiopoietin-1 promotes endothelial cell pro-
liferation and migration through AP-1-dependent autocrine
production of interleukin-8. Blood 2008, 111:4145-4154.
92. Daly C, Wong V, Burova E, Wei Y, Zabski S, Griffiths J, Lai KM,
Lin HC, Ioffe E, Yancopoulos GD, Rudge JS: Angiopoietin-1
modulates endothelial cell function and gene expression via
the transcription factor FKHR (FOXO1). Genes Dev 2004, 18:
1060-1071.
93. Tadros A, Hughes DP, Dunmore BJ, Brindle NP: ABIN-2 protects
endothelial cells from death and has a role in the antiapop-
totic effect of angiopoietin-1. Blood 2003, 102:4407-4409.
94. Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, Hussain
SN: Roles of reactive oxygen species in angiopoietin-1/tie-2
receptor signaling. FASEB J 2005, 19:1728-1730.
95. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T,
Shibuya M, Takakura N, Koh GY, Mochizuki N: Differential func-
tion of Tie2 at cell-cell contacts and cell-substratum contacts
regulated by angiopoietin-1. Nat Cell Biol 2008, 10:513-526.
96. Lobov IB, Brooks PC, Lang RA: Angiopoietin-2 displays VEGF-
dependent modulation of capillary structure and endothelial
cell survival in vivo. Proc Natl Acad Sci USA 2002, 99:11205-
11210.
97. Nguyen VP, Chen SH, Trinh J, Kim H, Coomber BL, Dumont DJ:
Differential response of lymphatic, venous and arterial
endothelial cells to angiopoietin-1 and angiopoietin-2. BMC
Cell Biol 2007, 8:10.
98. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI,
Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD,
Stewart DJ: Biological action of angiopoietin-2 in a fibrin
matrix model of angiogenesis is associated with activation of
Tie2. Cardiovasc Res 2001, 49:659-670.
99. Imhof BA, urrand-Lions M: Angiogenesis and inflammation face
off. Nat Med 2006, 12:171-172.
100.Frantz S, Vincent KA, Feron O, Kelly RA: Innate immunity and
angiogenesis. Circ Res 2005, 96:15-26.
101.Hamik A, Wang B, Jain MK: Transcriptional regulators of angio-
genesis. Arterioscler Thromb Vasc Biol 2006, 26:1936-1947.
102.Davis GE, Senger DR: Extracellular matrix mediates a molecu-
lar balance between vascular morphogenesis and regression.
Curr Opin Hematol 2008, 15:197-203.
103.Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG: The Tie-2
ligand angiopoietin-2 destabilizes quiescent endothelium
through an internal autocrine loop mechanism. J Cell Sci
2005, 118:771-780.
104.Aplin AC, Gelati M, Fogel E, Carnevale E, Nicosia RF: Angiopoi-
etin-1 and vascular endothelial growth factor induce expres-
sion of inflammatory cytokines before angiogenesis. Physiol
Genomics 2006, 27:20-28.
105.Uemura A, Ogawa M, Hirashima M, Fujiwara T, Koyama S, Takagi
H, Honda Y, Wiegand SJ, Yancopoulos GD, Nishikawa S:
Recombinant angiopoietin-1 restores higher-order architec-
ture of growing blood vessels in mice in the absence of mural
cells. J Clin Invest 2002, 110:1619-1628.
106.Ramsauer M, D’Amore PA: Contextual role for angiopoietins
and TGFbeta1 in blood vessel stabilization. J Cell Sci 2007,
120:1810-1817.
107.Kwak HJ, So JN, Lee SJ, Kim I, Koh GY: Angiopoietin-1 is an
apoptosis survival factor for endothelial cells. FEBS Lett 1999,
448:249-253.
108.Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre
PC, Yancopoulos GD, Sessa WC: Direct actions of angiopoi-
etin-1 on human endothelium: evidence for network stabiliza-
tion, cell survival, and interaction with other angiogenic
growth factors. Lab Invest 1999, 79:213-223.
109.Papapetropoulos A, Fulton D, Mahboubi K, Kalb RG, O’Connor
DS, Li F, Altieri DC, Sessa WC: Angiopoietin-1 inhibits
endothelial cell apoptosis via the Akt/survivin pathway. J Biol
Chem 2000, 275:9102-9105.
110.Morrow D, Cullen JP, Cahill PA, Redmond EM: Cyclic strain reg-
ulates the Notch/CBF-1 signaling pathway in endothelial
cells: role in angiogenic activity. Arterioscler Thromb Vasc Biol
2007, 27:1289-1296.
111.Murdoch C, Tazzyman S, Webster S, Lewis CE: Expression of
Tie-2 by human monocytes and their responses to angiopoi-
etin-2. J Immunol 2007, 178:7405-7411.
112.Chen-Konak L, Guetta-Shubin Y, Yahav H, Shay-Salit A, Zilber-
man M, Binah O, Resnick N: Transcriptional and post-transla-
tion regulation of the Tie1 receptor by fluid shear stress
changes in vascular endothelial cells. FASEB J 2003,  17:
2121-2123.
113.Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD,
Isner JM: Chemotactic properties of angiopoietin-1 and -2,
ligands for the endothelial-specific receptor tyrosine kinase
Tie2. J Biol Chem 1998, 273:18514-18521.
114.Rao S, Lobov IB, Vallance JE, Tsujikawa K, Shiojima I, Akunuru S,
Walsh K, Benjamin LE, Lang RA: Obligatory participation of
macrophages in an angiopoietin 2-mediated cell death
switch. Development 2007, 134:4449-4458.
115.Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V,
Cirino G, Papapetropoulos A: Angiopoietin-2 causes inflamma-
tion in vivo by promoting vascular leakage. J Pharmacol Exp
Ther 2005, 314:738-744.
116.Feraud O, Mallet C, Vilgrain I: Expressional regulation of the
angiopoietin-1 and -2 and the endothelial-specific receptor
tyrosine kinase Tie2 in adrenal atrophy: a study of adrenocor-
ticotropin-induced repair. Endocrinology 2003, 144:4607-4615.
117.Fiedler U, Augustin HG: Angiopoietins: a link between angio-
genesis and inflammation. Trends Immunol 2006, 27:552-558.
118.Baffert F, Le T, Thurston G, McDonald DM: Angiopoietin-1
decreases plasma leakage by reducing number and size of
endothelial gaps in venules. Am J Physiol Heart Circ Physiol
2006, 290:H107-H118.
119.Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer
N, Holash J, McDonald DM, Yancopoulos GD: Angiopoietin-1
protects the adult vasculature against plasma leakage. Nat
Med 2000, 6:460-463.
120.Kim I, Oh JL, Ryu YS, So JN, Sessa WC, Walsh K, Koh GY:
Angiopoietin-1 negatively regulates expression and activity of
tissue factor in endothelial cells. FASEB J 2002, 16:126-128.
121.Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kas-
minkas L, Rudge J, Yancopoulos G, Vadas MA: Angiopoietin-1 is
an antipermeability and anti-inflammatory agent in vitro and
targets cell junctions. Circ Res 2000, 87:603-607.
122.Kim I, Moon SO, Park SK, Chae SW, Koh GY: Angiopoietin-1
reduces VEGF-stimulated leukocyte adhesion to endothelial
cells by reducing ICAM-1, VCAM-1, and E-selectin expression.
Circ Res 2001, 89:477-479.
123.Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A:
Angiopoietin-1 inhibits endothelial permeability, neutrophil
adherence and IL-8 production. Br J Pharmacol 2003, 139:329-
336.
124.Satchell SC, Anderson KL, Mathieson PW: Angiopoietin 1 and
vascular endothelial growth factor modulate human glomeru-
lar endothelial cell barrier properties. J Am Soc Nephrol 2004,
15:566-574.
125.Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S,
Thurston G, Gale NW, Witzenrath M, Rosseau S, Suttorp N,
Sobke A, Herrmann M, Preissner KT, Vajkoczy P, Augustin HG:
Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and
has a crucial role in the induction of inflammation. Nat Med
2006, 12:235-239.
126.Park YS, Kim NH, Jo I: Hypoxia and vascular endothelial
growth factor acutely up-regulate angiopoietin-1 and Tie2
mRNA in bovine retinal pericytes. Microvasc Res 2003, 65:125-
131.
127.Pichiule P, Chavez JC, LaManna JC: Hypoxic regulation of
angiopoietin-2 expression in endothelial cells. J Biol Chem
2004, 279:12171-12180.
128.Mofarrahi M, Nouh T, Qureshi S, Guillot L, Mayaki D, Hussain SN:
Regulation of angiopoietin expression by bacterial
lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 2008,
294:L955-L963.
129.Karmpaliotis D, Kosmidou I, Ingenito EP, Hong K, Malhotra A,
Sunday ME, Haley KJ: Angiogenic growth factors in the patho-
physiology of a murine model of acute lung injury. Am J
Physiol Lung Cell Mol Physiol 2002, 283:L585-L595.
130.Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ:
Prevention of LPS-induced acute lung injury in mice by mes-
enchymal stem cells overexpressing angiopoietin 1. PLoS
Med 2007, 4:e269.
131.Hangai M, He S, Hoffmann S, Lim JI, Ryan SJ, Hinton DR:
Sequential induction of angiogenic growth factors by TNF-
alpha in choroidal endothelial cells. J Neuroimmunol 2006,
171:45-56.
Available online http://ccforum.com/content/13/2/207
Page 11 of 13
(page number not for citation purposes)132.Kim I, Kim JH, Ryu YS, Liu M, Koh GY: Tumor necrosis factor-
alpha upregulates angiopoietin-2 in human umbilical vein
endothelial cells. Biochem Biophys Res Commun 2000, 269:
361-365.
133.Hashimoto T, Wu Y, Boudreau N, Li J, Matsumoto M, Young W:
Regulation of tie2 expression by angiopoietin—potential feed-
back system. Endothelium 2004, 11:207-210.
134.Mangan SH, Campenhout AV, Rush C, Golledge J: Osteoprote-
gerin upregulates endothelial cell adhesion molecule
response to tumor necrosis factor-alpha associated with
induction of angiopoietin-2. Cardiovasc Res 2007, 76:494-505.
135.Maliba R, Brkovic A, Neagoe PE, Villeneuve LR, Sirois MG:
Angiopoietin-mediated endothelial P-selectin translocation:
cell signaling mechanisms. J Leukoc Biol 2008, 83:352-360.
136.Bezuidenhout L, Bracher M, Davison G, Zilla P, Davies N: Ang-2
and PDGF-BB cooperatively stimulate human peripheral
blood monocyte fibrinolysis. J Leukoc Biol 2007,  81:1496-
1503.
137.Lemieux C, Maliba R, Favier J, Theoret JF, Merhi Y, Sirois MG:
Angiopoietins can directly activate endothelial cells and neu-
trophils to promote proinflammatory responses. Blood 2005,
105:1523-1530.
138.Childs EW, Tharakan B, Byrge N, Tinsley JH, Hunter FA, Smythe
WR: Angiopoietin-1 inhibits intrinsic apoptotic signaling and
vascular hyperpermeability following hemorrhagic shock. Am
J Physiol Heart Circ Physiol 2008, 294:H2285-H2295.
139.Dallabrida SM, Ismail N, Oberle JR, Himes BE, Rupnick MA:
Angiopoietin-1 promotes cardiac and skeletal myocyte sur-
vival through integrins. Circ Res 2005, 96:e8-24.
140.Childs EW, Tharakan B, Hunter FA, Tinsley JH, Cao X: Apoptotic
signaling induces hyperpermeability following hemorrhagic
shock. Am J Physiol Heart Circ Physiol 2007,  292:H3179-
H3189.
141.Tharakan B, Holder-Haynes JG, Hunter FA, Childs EW: Alpha
lipoic acid attenuates microvascular endothelial cell hyperper-
meability by inhibiting the intrinsic apoptotic signaling. Am J
Surg 2008, 195:174-178.
142.Davidson MT, Deitch EA, Lu Q, Hasko G, Abungu B, Nemeth ZH,
Zaets SB, Gaspers LD, Thomas AP, Xu DZ: Trauma-hemor-
rhagic shock mesenteric lymph induces endothelial apoptosis
that involves both caspase-dependent and caspase-indepen-
dent mechanisms. Ann Surg 2004, 240:123-131.
143.van der Heijden M, Versteilen AM, Sipkema P, van Nieuw Ameron-
gen GP, Musters RJ, Groeneveld AB: Rho-kinase-dependent F-
actin rearrangement is involved in the inhibition of
PI3-kinase/Akt during ischemia-reperfusion-induced endo-
thelial cell apoptosis. Apoptosis 2008, 13:404-412.
144.Serini G, Napione L, Arese M, Bussolino F: Besides adhesion:
new perspectives of integrin functions in angiogenesis. Car-
diovasc Res 2008, 78:213-222.
145.Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO:
Direct cell adhesion to the angiopoietins mediated by inte-
grins. J Biol Chem 2001, 276:26516-26525.
146.Weber CC, Cai H, Ehrbar M, Kubota H, Martiny-Baron G, Weber
W, Djonov V, Weber E, Mallik AS, Fussenegger M, Frei K, Hubbell
JA, Zisch AH: Effects of protein and gene transfer of the
angiopoietin-1 fibrinogen-like receptor-binding domain on
endothelial and vessel organization. J Biol Chem 2005, 280:
22445-22453.
147.Dejana E, Orsenigo F, Lampugnani MG: The role of adherens
junctions and VE-cadherin in the control of vascular perme-
ability. J Cell Sci 2008, 121:2115-2122.
148.Shay-Salit A, Shushy M, Wolfovitz E, Yahav H, Breviario F, Dejana
E, Resnick N: VEGF receptor 2 and the adherens junction as a
mechanical transducer in vascular endothelial cells. Proc Natl
Acad Sci USA 2002, 99:9462-9467.
149.Wang Y, Pampou S, Fujikawa K, Varticovski L: Opposing effect
of angiopoietin-1 on VEGF-mediated disruption of endothelial
cell-cell interactions requires activation of PKC beta. J Cell
Physiol 2004, 198:53-61.
150.Gavard J, Patel V, Gutkind JS: Angiopoietin-1 prevents VEGF-
induced endothelial permeability by sequestering Src through
mDia. Dev Cell 2008, 14:25-36.
151.Cascone I, Napione L, Maniero F, Serini G, Bussolino F: Stable
interaction between alpha5beta1 integrin and Tie2 tyrosine
kinase receptor regulates endothelial cell response to Ang-1.
J Cell Biol 2005, 170:993-1004.
152.David S, Kumpers P, Hellpap J, Horn R, Holger L, Kielstein JT,
Haller H: Elevated serum angiopoietin-2 correlates with degree
of arteriosclerosis in CKD V patients. J Am Soc Nephrol 2007,
18:SU-PO250 [http://www.asn-online.org/education_and_meetings/
renal_week/archives/2007-abstracts-archive.pdf]
153.Pfaff D, Fiedler U, Augustin HG: Emerging roles of the
angiopoietin-Tie and the ephrin-Eph systems as regulators of
cell trafficking. J Leukoc Biol 2006, 80:719-726.
154.Methe H, Hess S, Edelman ER: Endothelial immunogenicity: a
matter of matrix microarchitecture. Thromb Haemost 2007, 98:
278-282.
155.Methe H, Balcells M, Alegret MC, Santacana M, Molins B, Hamik
A, Jain MK, Edelman ER: Vascular bed origin dictates flow
pattern regulation of endothelial adhesion molecule expres-
sion. Am J Physiol Heart Circ Physiol 2007, 292:H2167-H2175.
156.Griffioen AW, Molema G: Angiogenesis: potentials for pharma-
cologic intervention in the treatment of cancer, cardiovascular
diseases, and chronic inflammation. Pharmacol Rev 2000, 52:
237-268.
157.Griffin RJ, Molema G, Dings RP: Angiogenesis treatment, new
concepts on the horizon. Angiogenesis 2006, 9:67-72.
158.Niu Q, Perruzzi C, Voskas D, Lawler J, Dumont DJ, Benjamin LE:
Inhibition of Tie-2 signaling induces endothelial cell apopto-
sis, decreases Akt signaling, and induces endothelial cell
expression of the endogenous anti-angiogenic molecule,
thrombospondin-1. Cancer Biol Ther 2004, 3:402-405.
159.Kerbel RS: Tumor angiogenesis. N Engl J Med 2008,  358:
2039-2049.
160.Chae JK, Kim I, Lim ST, Chung MJ, Kim WH, Kim HG, Ko JK, Koh
GY:  Coadministration of angiopoietin-1 and vascular
endothelial growth factor enhances collateral vascularization.
Arterioscler Thromb Vasc Biol 2000, 20:2573-2578.
161.Ryu JK, Cho CH, Shin HY, Song SU, Oh SM, Lee M, Piao S, Han
JY, Kim IH, Koh GY, Suh JK: Combined angiopoietin-1 and vas-
cular endothelial growth factor gene transfer restores cav-
ernous angiogenesis and erectile function in a rat model of
hypercholesterolemia. Mol Ther 2006, 13:705-715.
162.Holash J, Thurston G, Rudge JS, Yancopoulos GD, Adjei AA,
Bergers G, Pytowski B, Pegram M, Gordon MS: Inhibitors of
growth factor receptors, signaling pathways and angiogene-
sis as therapeutic molecular agents. Cancer Metastasis Rev
2006, 25:243-252.
163.Koh GY, Kim I, Kwak HJ, Yun MJ, Leem JC: Biomedical signifi-
cance of endothelial cell specific growth factor, angiopoietin.
Exp Mol Med 2002, 34:1-11.
164.Hashimoto T, Pittet JF: Angiopoietin-2: modulator of vascular
permeability in acute lung injury? PLoS Med 2006, 3:e113.
165.Cho CH, Kammerer RA, Lee HJ, Steinmetz MO, Ryu YS, Lee SH,
Yasunaga K, Kim KT, Kim I, Choi HH, Kim W, Kim SH, Park SK,
Lee GM, Koh GY: COMP-Ang1: a designed angiopoietin-1
variant with nonleaky angiogenic activity. Proc Natl Acad Sci
USA 2004, 101:5547-5552.
166.Lee S, Kim W, Moon SO, Sung MJ, Kim DH, Kang KP, Jang KY,
Lee SY, Park BH, Koh GY, Park SK: Renoprotective effect of
COMP-angiopoietin-1 in db/db mice with type 2 diabetes.
Nephrol Dial Transplant 2007, 22:396-408.
167.Tuo QH, Zeng H, Stinnett A, Yu H, Aschner JL, Liao DF, Chen JX:
Critical role of angiopoietins/Tie-2 in hyperglycemic exacer-
bation of myocardial infarction and impaired angiogenesis.
Am J Physiol Heart Circ Physiol 2008, 294:H2547-H2557.
168.Thebaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G,
Eaton F, Hashimoto K, Harry G, Haromy A, Korbutt G, Archer SL:
Vascular endothelial growth factor gene therapy increases
survival, promotes lung angiogenesis, and prevents alveolar
damage in hyperoxia-induced lung injury: evidence that
angiogenesis participates in alveolarization. Circulation 2005,
112:2477-2486.
169.Witzenbichler B, Westermann D, Knueppel S, Schultheiss HP,
Tschope C: Protective role of angiopoietin-1 in endotoxic
shock. Circulation 2005, 111:97-105.
170.Lee JS, Song SH, Kim JM, Shin IS, Kim KL, Suh YL, Kim HZ, Koh
GY, Byun J, Jeon ES, Suh W, Kim DK: Angiopoietin-1 prevents
hypertension and target organ damage through its interaction
with endothelial Tie2 receptor. Cardiovasc Res 2008, 78:572-
580.
171.Aghai ZH, Faqiri S, Saslow JG, Nakhla T, Farhath S, Kumar A,
Eydelman R, Strande L, Stahl G, Leone P, Bhandari V: Angiopoi-
Critical Care    Vol 13 No 2 van Meurs et al.
Page 12 of 13
(page number not for citation purposes)etin 2 concentrations in infants developing bronchopulmonary
dysplasia: attenuation by dexamethasone. J Perinatol 2008,
28:149-155.
172.Sarraf-Yazdi S, Mi J, Moeller BJ, Niu X, White RR, Kontos CD, Sul-
lenger BA, Dewhirst MW, Clary BM: Inhibition of in vivo tumor
angiogenesis and growth via systemic delivery of an
angiopoietin 2-specific RNA aptamer. J Surg Res 2008,
146:16-23.
173.Grimm D, Kay MA: Therapeutic application of RNAi: is mRNA
targeting finally ready for prime time? J Clin Invest 2007, 117:
3633-3641.
174.Dewachter L, Adnot S, Fadel E, Humbert M, Maitre B, Barlier-Mur
AM, Simonneau G, Hamon M, Naeije R, Eddahibi S: Angiopoi-
etin/Tie2 pathway influences smooth muscle hyperplasia in
idiopathic pulmonary hypertension. Am J Respir Crit Care Med
2006, 174:1025-1033.
175.Nomura S, Kanazawa H, Hirata K, Iwao H, Yoshikawa J: Relation-
ship between vascular endothelial growth factor and angio-
poietin-2 in asthmatics before and after inhaled beclo-
methasone therapy. J Asthma 2005, 42:141-146.
176.Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S,
Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitri-
adou EM, Kalpadakis C, Tsionos K, Panayiotidis P, Dimopoulos
MA, Pangalis GA, Kyrtsonis MC: Normalization of the serum
angiopoietin-1 to angiopoietin-2 ratio reflects response in
refractory/resistant multiple myeloma patients treated with
bortezomib. Haematologica 2008, 93:451-454.
177.Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, Oh YJ,
Hwang SC: Serum angiopoietin-2 as a clinical marker for lung
cancer. Chest 2007, 132:200-206.
178.Kumpers P, Koenecke C, Hecker H, Hellpap J, Horn R, Verhagen
W, Buchholz S, Hertenstein B, Krauter J, Eder M, David S,
Gohring G, Haller H, Ganser A: Angiopoietin-2 predicts
disease-free survival after allogeneic stem cell transplanta-
tion in patients with high-risk myeloid malignancies. Blood
2008, 112:2139-2148.
179.Ledford H: The full cycle. Nature 2008, 453:843-845.
180.Gallagher DC, Bhatt RS, Parikh SM, Patel P, Seery V, McDermott
DF, Atkins MB, Sukhatme VP: Angiopoietin 2 is a potential
mediator of high-dose interleukin 2-induced vascular leak.
Clin Cancer Res 2007, 13:2115-2120.
181.Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K,
Koch I, Pascu M, Wiedenmann B, Berg T, Schott E: Angiopoi-
etin-2 serum levels are elevated in patients with liver cirrhosis
and hepatocellular carcinoma. Am J Gastroenterol 2007, 102:
2471-2481.
Available online http://ccforum.com/content/13/2/207
Page 13 of 13
(page number not for citation purposes)